Identification of a Candidate Standard Strain of Severe Fever with Thrombocytopenia Syndrome Virus for Vaccine Quality Control in China Using a Cross-Neutralization Assay.

Zheng Jia,Xiaohong Wu,Ling Wang,Xiuling Li,Xinxian Dai,Mifang Liang,Shouchun Cao,Yan Kong,Jingjing Liu,Yuhua Li,Junzhi Wang
DOI: https://doi.org/10.1016/j.biologicals.2017.01.005
IF: 1.76
2017-01-01
Biologicals
Abstract:Severe fever with thrombocytopenia syndrome (SFTS) is caused by a phlebovirus of the Bunyaviridae family, which is designated as SFTS virus (SFTSV). To our knowledge, no efficient SFTSV vaccine exists. Here, we report the identification of a standard virus strain for the eight major SFTSV strains circulating in China for use in evaluating the SFTSV vaccine. Rabbits were immunized with the SFTSV strains and the cross-neutralization capacities of SFTSV anti-sera were determined in microculture cytopathic effect (CPE)-inhibition assays. The mean cross-neutralization capacity of the eight SFTSV anti-sera ranged from 62.4 to 142.6%, compared to autologous strains. The HB29 strain demonstrated strong cross-reactivity with heterologous antibodies, and 33 serum samples from SFTS patients efficiently neutralized HB29, suggesting its broad cross-reactivity. In addition, HB29 demonstrated good replication in Vero and MRC5 cells (8.0 and 6.0 lg 50% cell culture-infectious dose/mL, respectively) and significant CPE, which satisfied the requirements for a standard virus strain. The HB29 isolate was proven identical to the reported HB29 strain by DNA sequencing, and showed high homology in the S segments with other SFTSV strains (94.8-99.7%). Our results suggest that HB29 may be the best candidate standard strain for use in SFTS vaccine development in China. (C) 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
What problem does this paper attempt to address?